Author name: Jane Nasol

Kodiak Sciences’ Positive Eye Disease Data: Should Investors Buy the Rally? The biotech sector is no stranger to dramatic swings, and Kodiak Sciences Inc. (KOD) just provided a textbook example. After announcing positive topline data from its pivotal GLEAM and GLIMMER studies for its lead candidate, **tarcocimab tedromer**, in diabetic eye diseases, the company’s stock […]

Kodiak Sciences Stock Surges After Positive Eye Disease Trial Results In a significant development for both patients and investors, Kodiak Sciences Inc. (NASDAQ: KOD) saw its stock price rocket upwards following the announcement of highly promising Phase III clinical trial data. The biopharmaceutical company, focused on novel treatments for retinal diseases, reported that its lead

BYD’s God’s Eye Self-Driving System Faces Major Technical Setbacks The race for autonomous driving supremacy is a marathon, not a sprint, and even the frontrunners can stumble. BYD, the Chinese electric vehicle giant that recently dethroned Tesla in global EV sales, is facing a significant hurdle in its quest for technological dominance. Its highly anticipated

Eye Floaters Could Signal a Serious Retinal Detachment Risk We’ve all experienced them at some point: those tiny, shadowy specks, cobwebs, or squiggly lines that drift across your field of vision, especially when you look at a bright, plain surface like a blue sky or a white wall. Known as eye floaters, they are often

How a Routine Eye Test Saved a Life by Detecting a Brain Tumor We often think of an eye exam as a simple check for glasses or a screening for common conditions like cataracts. It’s a routine part of healthcare, sometimes even postponed when life gets busy. But what if that 30-minute appointment could do

Ocugen Stock Drops After Eye Disease Gene Therapy Trial Disappoints The world of biotechnology is a high-stakes arena, where a single clinical trial result can send a company’s valuation soaring or plummeting. This volatile reality hit home for Ocugen, Inc. (NASDAQ: OCGN) this week, as the company’s shares experienced a sharp decline following the release